Shanghai Aidefa Pharmacy Co. Ltd.

The bioequivalence of a single oral dose of 20 mg of clobazam oral suspension provided by Shanghai Aifa Pharmaceutical Co., Ltd. (test preparation, trade name: Tapclob®, strength: 10 mg/5 mL) or a single oral dose of 20 mg of clobazam oral suspension certified by Lundbeck Pharmaceuticals LLC (reference preparation, trade name: Onfi®, strength: 2.5 mg/mL) was investigated under fasting and postprandial conditions.

The pharmacokinetic characteristics of healthy subjects were investigated by taking a single bag of mesalazine sustained-release granules (test preparation, strength: 1g, calculated as mesalazine) provided by Shanghai Aifa Pharmaceutical Co., Ltd. orally under fasting or postprandial state and taking a single bag of mesalazine sustained-release granules (reference preparation, trade name: Pentasa®, strength: 1g, calculated as mesalazine) certified by Ferring S.A.S. orally under the same state. The differences in pharmacokinetic parameters AUC and Cmax between the two preparations were compared, and the bioequivalence of the two preparations was preliminarily evaluated.

This study aimed to investigate the pharmacokinetic characteristics of fenofibrate capsules (0.2 g) developed and produced by Shanghai Aifa Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using fenofibrate capsules (Lipingzhi®, 200 mg) certified by Abbott Laboratories Limited as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.